CD274 and Adrenal insufficiency: Among three PD-L1 drugs, atezolizumab was mostly associated with MNDs, with 13 detected signals and IC025/ROR025 ranging from 0.19/1.22 for decreased appetite to 3.22/10.14 for adrenal insufficiency.